entinostat has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rahmani, M | 1 |
| Yu, C | 1 |
| Reese, E | 1 |
| Ahmed, W | 1 |
| Hirsch, K | 1 |
| Dent, P | 1 |
| Grant, S | 1 |
1 other study available for entinostat and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.
Topics: Apoptosis; Benzamides; Butyrates; Chromones; Complement Membrane Attack Complex; Complement System P | 2003 |